Get started
Author

François Therrien

Observed names: F. Therrien, Francois Therrien, Therrien, François
ORCID: 0000-0002-6512-4333
Observed ORCID: 0000-0002-6512-4333
OpenAlex ID: A5002387457
A PET Study of Dopamine D2 and Serotonin 5-HT2 Receptor Occupancy in Patients With Schizophrenia Treated With Therapeutic Doses of Ziprasidone
2004 · David Mamo, Shitij Kapur, et al. · American Journal of Psychiatry · 191
Pregabalin for Peripheral Neuropathic Pain: A Multicenter, Enriched Enrollment Randomized Withdrawal Placebo-controlled Trial
2010 · Ian Gilron, Dalia Wajsbrot, et al. · Clinical Journal of Pain · 70
Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: A post hoc analysis of four clinical studies
2022 · Martin A. Katzman, François Therrien, et al. · Journal of Affective Disorders · 12
PDF
Effects of Adjunctive Brexpiprazole on Individual Depressive Symptoms and Functioning in Patients With Major Depressive Disorder and Anxious Distress: Post Hoc Analysis of Three Placebo-Controlled Studies
2024 · Roger S. McIntyre, Suzy Bubolic, et al. · Journal of Clinical Psychopharmacology · 11
Exploring life engagement from the perspective of patients with major depressive disorder: a study using patient interviews
2022 · François Therrien, Stine R. Meehan, et al. · Journal of Patient-Reported Outcomes · 11
PDF
Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies
2022 · Daniel Schöttle, Guerline Clerzius, et al. · European Psychiatry · 11
PDF
Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: Post hoc analysis of Inventory of Depressive Symptomatology Self-Report data
2023 · Roger S. McIntyre, François Therrien, et al. · Journal of Psychiatric Research · 10
Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d'appoint pour l'engagement dans la vie des patients souffrant de trouble dépressif majeur: une étude interventionnelle canadienne ouverte de phase 4
2024 · François Therrien, Caroline Ward, et al. · The Canadian Journal of Psychiatry · 9
Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)
2023 · Oloruntoba Oluboka, Guerline Clerzius, et al. · BMC Psychiatry · 9
PDF
Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study
2022 · Howard C. Margolese, Matthieu Boucher, et al. · BMC Psychiatry · 7
PDF
The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study
2014 · Pierre Chue, Francine S. Mandel, et al. · Current Medical Research and Opinion · 6
Long-term effectiveness of aripiprazole once monthly on functioning and quality of life in schizophrenia: results of year 2 of the ReLiAM study
2024 · Marc-André Roy, François Therrien, et al. · BMC Psychiatry · 2
PDF
BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study)
2023 · Daniel Schöttle, Wolfgang Janetzky, et al. · BMC Psychiatry · 2
PDF
Treatment patterns of agitation associated with Alzheimer’s dementia (AAD) patients in Canada
2026 · Veronique Littmann-Crites, A. Marilise Marrache, et al. · International Psychogeriatrics · 1
Patient-reported efficacy of adjunctive brexpiprazole in major depressive disorder in a phase 4, open-label, interventional study
2025 · François Therrien, Pratap Chokka, et al. · Current Medical Research and Opinion · 1
T50. Symptomatic and Functional Response to Brexpip Razole Treatment in Patients With Acute Schizophrenia by Age
2018 · Catherine Weiss, Erin MacKenzie, et al. · Schizophrenia Bulletin · 1
PDF
Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence
2026 · Roger S. McIntyre, Masaki Kato, et al. · CNS Drugs
PDF
Patient life engagement as a treatment goal in adults with major depressive disorder: a plain language summary
2026 · Roger S. McIntyre, Dave Gallson, et al. · Future Neurology
PDF
Effects of Adjunctive Brexpiprazole in Major Depressive Disorder Analyzed by Baseline Anxiety Level: Post Hoc Analysis of a Phase 4 Study
2025 · François Therrien, Caroline Ward, et al. · Journal of Clinical Psychopharmacology
Treatment Patterns of Agitation associated with Alzheimer's Dementia (AAD) Patients in Canada
2025 · Veronique Littmann, Francois Therrien, et al. · Alzheimer s & Dementia
PDF
Effects of adjunctive brexpiprazole in major depressive disorder analysed by baseline anxiety level: post hoc analysis of an open-label study
2024 · F. Therrien, C. Ward, et al. · Neuroscience Applied
Improvement of functioning in patients with schizophrenia: Real-world effectiveness of aripiprazole once-monthly (REACT study)
2023 · Oloruntoba Oluboka, Guerline Clerzius, et al. · Research Square
PDF
Effects of adjunctive brexpiprazole on patient-reported efficacy measures in major depressive disorder: a phase 4, open-label, interventional study
2023 · E. MacKenzie, C. Ward, et al. · Neuroscience Applied
Correlations between patient life engagement and other outcomes in a phase 4 study of adjunctive brexpiprazole for major depressive disorder
2023 · F. Therrien, C. Ward, et al. · Neuroscience Applied
Works count: 31
Citation count: 354
H-index: 9
I10-index: 7
Year
Topic
Type